#CurePF
LightNews LightNews
kerrijohannson.bsky.social
#ICLAF ideas…. Train conference! 🫁Multiple venues, rail transport, themes by location, #CurePF in motion 😊
(H/T🎩 @odedrechavi.bsky.social)

@ipfdoc.bsky.social @kaminskimed.bsky.social @rachelkputman.bsky.social @jskim8223.bsky.social
@gilliangoobie.bsky.social
odedrechavi.bsky.social Oded Rechavi @odedrechavi.bsky.social · Apr 1
Who does that? We rented a train JUST for the conference, that will take the participants from Prague to the woods of Bohemia. There'll be talks ON THE TRAIN. In Prague we'll have 5 locations with different atmospheres.
#theconferencetoendallconferences Register now:
woodstock.img.cas.cz
April 2, 2025 at 4:31 AM
msmacrophage.bsky.social
Thank you @drdayjee.bsky.social for an exceptional talk on ethnic and racial disparities on pulmonary fibrosis @ #TheFirestone. So important to understand how time of diagnosis, progression, and pathology differ for both clinicians and researchers. #lungsky #pulmsky #CurePF #lungs
April 15, 2025 at 1:53 PM
kerrijohannson.bsky.social
The Impact of Pulmonary Fibrosis on Sex and Sexual Function - A Multinational Mixed Methods Study

Just out in ERJ and led by Dr. Na'ama Avitzur
A 🧵👇
(key take-away 👉 sex matters to patients with PF and their disease impacts this)

#OpenAccess #CurePF #CureIPF
publications.ersnet.org/content/erj/...
Screen shot of title page
October 14, 2025 at 1:59 AM
kerrijohannson.bsky.social
For the new BlueSky members who have left #ILDTwitter I’ve updated this starter-pack to help you find key ILD and ILD-adjacent community members here. Pls comment if I’ve missed you and I’ll add you 🫁😊
#CurePF #CureIPF #ILD

go.bsky.app/8u4KcNo
November 14, 2024 at 3:22 AM
kerrijohannson.bsky.social
Now can we use CA-125 as a theragnostic biomarker of treatment response in patients with IPF? Why wouldn't we?

@ipfdoc.bsky.social @kaminskimed.bsky.social
#CurePF #CureIPF @ats-clinicalprobs.bsky.social @tkulkarni.bsky.social @jskim8223.bsky.social

pmc.ncbi.nlm.nih.gov/articles/pmi...
screenshot of study title. Effects of nintedanib on biomarkers in IPF in ERJ Open.
December 21, 2024 at 6:52 AM
kerrijohannson.bsky.social
#ILDSky #CureIPF #CurePF
Nintedanib for SSc-ILD at Scleroderma centres in the US.
Not one 🫁 MD on this paper 👀
Are Rheumatologists treating/managing ILD at your centres?
@jskim8223.bsky.social @ipfdoc.bsky.social @tkulkarni.bsky.social @istamina.bsky.social
Screen shot of the article title in Annals ATS and authorship
April 13, 2025 at 9:01 PM
drdayjee.bsky.social
What a lovely treat, to be welcomed on here by the greatest #CurePF warrior of them - @kaminskimed.bsky.social !!!

Finally making the leap into 2025 in style on @bsky.app ! 😎 🍾🥂
January 3, 2025 at 3:08 AM
mtfreeberg.bsky.social
Hi #AcademicSky 👋🏻 I’m a post doc studying mechanobiology and cellular metabolic reprogramming in pulmonary fibrosis 🫁👩🏻‍🔬 #curePF

I love to discuss fun science, writing, career development, women in science, and adventure!
September 28, 2023 at 10:30 AM
atsblueeditor.bsky.social
Impact of Environmental Exposures on the Development and Progression of Fibrotic ILD

Inhaled environmental exposures correspond to risk of pulmonary fibrosis and clinical outcomes such as acute exacerbations and mortality
@kerrijohannson.bsky.social #CurePF #medsky

🔗 tinyurl.com/mrynj6ds
April 14, 2025 at 5:21 PM
kaminskimed.bsky.social
Or even better a Queen Mary II conference - 6 days between New York and Southampton on an ocean liner - talks, discussions, gatherings, gala and black tie dinners and dances, as mornings in the gym or on the deck #CurePF 👇🏼
April 2, 2025 at 4:47 AM
tkulkarni.bsky.social
Please add me too! #CurePF
January 3, 2025 at 1:28 PM
kaminskimed.bsky.social
Really cool! Inhibition of epithelial cell YAP-TEAD/LOX signaling attenuates pulmonary fibrosis in preclinical models. From the team of Darcy Wagner, Oliver Eickelberg & Melanie Königshoff
#ScienceMatters #CurePF
www.nature.com/articles/s41...
Inhibition of epithelial cell YAP-TEAD/LOX signaling attenuates pulmonary fibrosis in preclinical models - Nature Communications
Extracellular matrix (ECM) remodeling is a hallmark of fibrosis thought to be driven by mesenchymal cells. Here, the authors discover that YAP-TEAD/LOX axis is activated in distal lung epithelial cells, which contributes to ECM remodeling in pre-clinical models of pulmonary fibrosis.
www.nature.com
October 5, 2025 at 6:29 AM
tkulkarni.bsky.social
The “why” behind every decision is the person in front of us. In this conversation, I joined the Leap Together podcast to discuss the real-world complexity for patients living with pulmonary fibrosis.

Listen here: lpcur.com/LeapTogether... 

#LeapTogetherPodcast #ClinicalTrials #curePF
November 12, 2025 at 8:04 PM
bibekgooptu.bsky.social
V happy to help screen first UK case for Scleroderma Research Foundation’s platform trial, assessing treatments for SSc-ILD, today #CurePF
Plenty of Rheum in the ILD house (and vice versa), amiright
@drpujamehta1.bsky.social?
January 14, 2025 at 6:15 PM
kerrijohannson.bsky.social
A pleasure to collaborate with all co-authors to create a true translational review of this topic ☺️

@gilliangoobie.bsky.social @ipfdoc.bsky.social @jskim8223.bsky.social and others not yet on 🦋

@ats-clinicalprobs.bsky.social @ats-eoph.bsky.social
#CurePF #CureIPF #AdvancesInILD
January 4, 2025 at 6:53 PM
tkulkarni.bsky.social
Amplification of patients voices is key to personalized care. Excited about our recent study highlighting the disease burden and critical gaps as we move towards patient focused management for individuals living with IPF #curePF bmcpulmmed.biomedcentral.com/articles/10....
Perspectives of people living with idiopathic pulmonary fibrosis: a qualitative and quantitative study - BMC Pulmonary Medicine
Background The antifibrotic therapies, pirfenidone and nintedanib, have been approved since 2014 for idiopathic pulmonary fibrosis (IPF), but in the United States only a quarter of people living with ...
bmcpulmmed.biomedcentral.com
May 9, 2025 at 12:29 PM
tkulkarni.bsky.social
Among other factors, this real-world study underscores the importance of addressing mental health in patients with IPF #curePF
atscommunity.bsky.social American Thoracic Society (ATS) @atscommunity.bsky.social · Nov 21
In idiopathic pulmonary fibrosis (IPF), lack of persistence in following antifibrotic therapy was linked to patient variables that included depression, lower DLCO, higher all-cause mortality, and worse transplant-free survival: Annals of the ATS.

www.pulmonologyadvisor.com/news/ipf-ant...
IPF Antifibrotic Therapy Discontinuation Linked to Depression, Lower DLCO
In IPF, antifibrotic therapy discontinuation was linked to patient variables that included depression, lower DLCO, and higher all-cause mortality.
www.pulmonologyadvisor.com
November 21, 2024 at 5:46 PM
drdayjee.bsky.social
Thank you for the opportunity to present at your clinical and research grand rounds! It was a great honor to interact with, and learn from you all!!! 🙏🏽 #CurePF
April 15, 2025 at 6:05 PM
kerrijohannson.bsky.social
Oscillometry is all the rage in lung function these days 🫁
If you're not quite sure what it is, this editorial might help!

#openaccess @bmj.com @ats-clinicalprobs.bsky.social #ILD #CurePF #CureIPF

bmjopenrespres.bmj.com/content/13/1...
February 27, 2026 at 5:38 PM
kerrijohannson.bsky.social
I’m sorry to hear about your FIL ❤️
Pulmonary fibrosis can be devastating. All of us working in the field (including our amazing patient partners) hope that the diagnostic tools, treatments, and overall management/support improve with the work we are doing 🙏 #CureIPF #CurePF
August 6, 2025 at 1:57 PM
ipfdoc.bsky.social
Tomorrow is the start of Pulmonary Fibrosis awareness month. To introduce it I went to @BBC in Manchester & was privileged to meet the inspirational Fiona who has PF. The work to #PreventPF & #CurePF continues. Thanks to @ActionPF for organising.
August 31, 2024 at 9:32 AM
mtfreeberg.bsky.social
In the final stretch of my next grant submission! Always grateful to fine tune my research direction and the input and support of my mentors.

My desk is a mess, I’ve had too much coffee and not enough water. But I’m happy about how it’s coming together! #curePF 🫁
October 5, 2023 at 1:36 PM
tkulkarni.bsky.social
Excited to share our review “Challenging the Status Quo for Therapeutic Clinical Trials in Fibrotic Interstitial Lung Diseases” where we discuss the current clinical trial landscape and explore emerging strategies to accelerate the development of therapies for fILD.

lnkd.in/guuRdp-w

#ILD #curePF
April 4, 2026 at 9:11 PM
stg-ildsupportgr.bsky.social
Thank you Ron and Maxine for telling your lived experience with IPF. So insightful and moving. #CurePF
January 27, 2025 at 12:34 AM
stg-ildsupportgr.bsky.social
Very sad to hear of the death of Rosemary Bechler, having struggled with #IPF for 5 years. We have lost an amazing and inspirational leader and campaigner for democracy and equality. #PF #curepf
https://www.opendemocracy.net/en/rosemary-bechler-obituary/?s=08
Attention Required! | Cloudflare
www.opendemocracy.net
January 27, 2025 at 12:24 AM